Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Yango is operational in Ethiopia

10/16/23 YNDX

Izhstal reported for 9 months of 2023 by RAS

10/16/23 IGST

Tatneft to build a terephthalic acid plant at TANECO Refinery

10/16/23 TATN

Rusal struggles to remain stable on the global market

10/16/23 RUAL

OGK-2 shareholders approved additional share issue

10/16/23 OGKB

Ingrad has changed its CEO

10/13/23 INGR

Qualcomm announced a quarterly dividend

10/13/23 QCOM

Activision Blizzard has been taken over by Microsoft

10/13/23 ATVI

Microsoft announced the closing of its deal with Activision Blizzard

10/13/23 MSFT

Progressive has reported for 9 months of 2023

10/13/23 PGR